Published in Trends Endocrinol Metab on April 22, 2010
In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril (2013) 1.59
Recurrence of cervical cancer in mice after selective estrogen receptor modulator therapy. Am J Pathol (2014) 1.49
Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.42
The Influence of Hormonal Factors on the Risk of Developing Cervical Cancer and Pre-Cancer: Results from the EPIC Cohort. PLoS One (2016) 1.40
Time since first sexual intercourse and the risk of cervical cancer. Int J Cancer (2011) 1.12
The role of co-factors in the progression from human papillomavirus infection to cervical cancer. Gynecol Oncol (2012) 1.07
Molecular transitions from papillomavirus infection to cervical precancer and cancer: Role of stromal estrogen receptor signaling. Proc Natl Acad Sci U S A (2015) 1.06
Oncogenic potential of Human Papillomavirus (HPV) and its relation with cervical cancer. Virol J (2011) 1.02
The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J Exp Med (2013) 1.01
Post-translational control of IL-1β via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathog (2013) 1.00
Requirement for stromal estrogen receptor alpha in cervical neoplasia. Horm Cancer (2012) 1.00
Progesterone signaling inhibits cervical carcinogenesis in mice. Am J Pathol (2013) 0.90
Enzymes of the AKR1B and AKR1C Subfamilies and Uterine Diseases. Front Pharmacol (2012) 0.84
Identification of protein biomarkers for cervical cancer using human cervicovaginal fluid. PLoS One (2014) 0.82
Roles of Dietary Phytoestrogens on the Regulation of Epithelial-Mesenchymal Transition in Diverse Cancer Metastasis. Toxins (Basel) (2016) 0.82
Aberrant promoter methylation and expression of UTF1 during cervical carcinogenesis. PLoS One (2012) 0.81
Requirement of estrogen receptor alpha DNA-binding domain for HPV oncogene-induced cervical carcinogenesis in mice. Carcinogenesis (2013) 0.81
Targeting female hormone receptors as cervical cancer therapy. Trends Endocrinol Metab (2015) 0.79
IGF axis and other factors in HPV-related and HPV-unrelated carcinogenesis (review). Oncol Rep (2014) 0.78
Human papillomavirus infections: warts or cancer? Cold Spring Harb Perspect Biol (2013) 0.78
GW627368X inhibits proliferation and induces apoptosis in cervical cancer by interfering with EP4/EGFR interactive signaling. Cell Death Dis (2016) 0.77
Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer. Oncoimmunology (2017) 0.77
Hospital recorded morbidity and breast cancer incidence: a nationwide population-based case-control study. PLoS One (2012) 0.77
Past and future of prophylactic ablation of the cervical squamocolumnar junction. Ecancermedicalscience (2015) 0.76
Loss of Keratin 17 induces tissue-specific cytokine polarization and cellular differentiation in HPV16-driven cervical tumorigenesis in vivo. Oncogene (2016) 0.76
Association between free testosterone levels and anal human papillomavirus types 16/18 infections in a cohort of men who have sex with men. PLoS One (2015) 0.75
Recurrence of cervical cancer and its resistance to progestin therapy in a mouse model. Oncotarget (2016) 0.75
Epistatic Interaction of CYP1A1 and COMT Polymorphisms in Cervical Cancer. Oxid Med Cell Longev (2015) 0.75
Prevalence of Anal Dysplasia in Human Immunodeficiency Virus-Infected Transgender Women. Sex Transm Dis (2017) 0.75
Effects of bisphenol compounds on the growth and epithelial mesenchymal transition of MCF-7 CV human breast cancer cells. J Biomed Res (2017) 0.75
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46
Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer (2002) 15.46
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol (2008) 6.20
Papillomaviruses in the causation of human cancers - a brief historical account. Virology (2009) 5.46
Estrogen receptors and human disease. J Clin Invest (2006) 4.91
Benefit of cervical screening at different ages: evidence from the UK audit of screening histories. Br J Cancer (2003) 4.14
The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer (2007) 3.99
'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature (1983) 3.63
Opinion: Comparative biology of mouse versus human cells: modelling human cancer in mice. Nat Rev Cancer (2003) 3.23
Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. BMJ (2009) 2.68
The human papillomavirus E7 oncoprotein. Virology (2008) 2.32
Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res (2003) 2.32
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle (2005) 2.20
Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A (1996) 2.06
Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocr Relat Cancer (2007) 2.01
Papillomavirus E6 proteins. Virology (2008) 1.70
Interaction of human papillomaviruses with the host immune system: a well evolved relationship. Virology (2008) 1.62
Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res (2000) 1.60
Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer (2006) 1.57
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A (2006) 1.57
Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A (2005) 1.50
Estrogen mediates Aurora-A overexpression, centrosome amplification, chromosomal instability, and breast cancer in female ACI rats. Proc Natl Acad Sci U S A (2004) 1.50
Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. Gynecol Oncol (2000) 1.39
The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res (2007) 1.39
Glucocorticoid-dependent oncogenic transformation by type 16 but not type 11 human papilloma virus DNA. Nature (1988) 1.28
Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice. Cancer Res (1999) 1.21
Requirement for estrogen receptor alpha in a mouse model for human papillomavirus-associated cervical cancer. Cancer Res (2008) 1.21
Critical roles for non-pRb targets of human papillomavirus type 16 E7 in cervical carcinogenesis. Cancer Res (2006) 1.21
Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer (2003) 1.19
Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol (1989) 1.18
p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res (2008) 1.06
Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A (2009) 1.04
Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res (2009) 1.04
Human papillomavirus E7 oncoprotein dysregulates steroid receptor coactivator 1 localization and function. J Virol (2006) 1.03
Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer (2000) 1.02
Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res (2009) 1.02
Role of steroid hormones in potentiating transformation of cervical cells by human papillomaviruses. Trends Microbiol (1994) 1.01
Human ADA3 binds to estrogen receptor (ER) and functions as a coactivator for ER-mediated transactivation. J Biol Chem (2004) 1.01
Estrogens and human papilloma virus oncogenes regulate human ether-à-go-go-1 potassium channel expression. Cancer Res (2009) 0.98
The positive predictive value of cervical smears in previously screened postmenopausal women: the Heart and Estrogen/progestin Replacement Study (HERS). Ann Intern Med (2000) 0.96
Diindolylmethane inhibits cervical dysplasia, alters estrogen metabolism, and enhances immune response in the K14-HPV16 transgenic mouse model. Cancer Epidemiol Biomarkers Prev (2009) 0.94
Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun (1996) 0.93
A case-control study of endogenous hormones and cervical cancer. Br J Cancer (2004) 0.93
Down-regulation of transforming growth factor-beta type II receptor (TGF-betaRII) protein and mRNA expression in cervical cancer. Mol Cancer (2008) 0.91
Tamoxifen and proliferation of vaginal and cervical epithelium in postmenopausal women with breast cancer. Eur J Obstet Gynecol Reprod Biol (1998) 0.91
Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. Cancer Res (1992) 0.88
Effects of short-term tamoxifen administration in patients with invasive cervical carcinoma. Anticancer Res (1994) 0.86
Human papillomavirus, cervical carcinogenesis and chemoprevention with Indole derivates - a review of pathomechanisms. Mol Nutr Food Res (2008) 0.86
In vitro response of cervical cancer cell lines CaSki, HeLa, and ME-180 to the antiestrogen tamoxifen. Gynecol Oncol (1988) 0.85
Incidence of cervical cytological abnormalities with aging in the women's health initiative: a randomized controlled trial. Obstet Gynecol (2006) 0.85
Evaluation of tamoxifen in persistent or recurrent nonsquamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer (2004) 0.85
Human papillomavirus E2 protein associates with nuclear receptors to stimulate nuclear receptor- and E2-dependent transcriptional activations in human cervical carcinoma cells. Int J Biochem Cell Biol (2006) 0.83
Neoplastic change of squamo-columnar junction in uterine cervix and vaginal epithelium by exogenous estrogen in hpv-18 URR E6/E7 transgenic mice. Gynecol Oncol (2003) 0.83
Regulation of nuclear receptor activities by two human papillomavirus type 18 oncoproteins, E6 and E7. Biochem Biophys Res Commun (2003) 0.82
Effects of tamoxifen and retinoic acid on cell growth and c-myc gene expression in human breast and cervical cancer cells. Anticancer Res (1998) 0.76
Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. N Engl J Med (2002) 10.80
Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer (2007) 10.29
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol (2012) 9.28
Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst (2005) 6.69
Human papillomavirus and oral cancer: the International Agency for Research on Cancer multicenter study. J Natl Cancer Inst (2003) 6.28
Global burden of human papillomavirus and related diseases. Vaccine (2012) 5.48
Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer (2011) 5.43
Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet (2002) 5.00
Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst (2007) 4.55
Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: a meta-analysis. Int J Cancer (2009) 4.28
Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem (2005) 4.18
Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst (2006) 4.14
Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. Lancet (2002) 3.96
Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS (2006) 3.76
Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine (2006) 3.72
Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev (2005) 3.40
Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer (2012) 3.35
Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2009) 3.33
Gallbladder cancer worldwide: geographical distribution and risk factors. Int J Cancer (2006) 3.27
Coffee drinking and hepatocellular carcinoma risk: a meta-analysis. Hepatology (2007) 3.22
Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol (2013) 3.00
Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res (2007) 2.93
Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev (2005) 2.86
Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J Natl Cancer Inst (2002) 2.75
Cervical cancer and use of hormonal contraceptives: a systematic review. Lancet (2003) 2.71
Prevalence and determinants of genital infection with papillomavirus, in female and male university students in Busan, South Korea. J Infect Dis (2004) 2.63
Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China. Lancet Oncol (2010) 2.61
Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. Lancet Oncol (2011) 2.52
Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol (2006) 2.51
Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology (2009) 2.44
Glycemic index: overview of implications in health and disease. Am J Clin Nutr (2002) 2.43
Dietary zinc and prostate cancer risk: a case-control study from Italy. Eur Urol (2007) 2.41
Chemoprevention of precancerous gastric lesions with antioxidant vitamin supplementation: a randomized trial in a high-risk population. J Natl Cancer Inst (2007) 2.36
Dissection of human papillomavirus E6 and E7 function in transgenic mouse models of cervical carcinogenesis. Cancer Res (2003) 2.32
Effect of obesity and other lifestyle factors on mortality in women with breast cancer. Int J Cancer (2008) 2.17
Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control (2008) 2.17
Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood (2009) 2.15
Human papillomavirus types in women with invasive cervical carcinoma by HIV status in Kenya. Int J Cancer (2008) 2.11
The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis (2005) 2.07
Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol (2003) 2.03
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Smoking and cervical cancer: pooled analysis of the IARC multi-centric case--control study. Cancer Causes Control (2003) 2.00
Total exposure and exposure rate effects for alcohol and smoking and risk of head and neck cancer: a pooled analysis of case-control studies. Am J Epidemiol (2009) 1.97
Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol (2003) 1.96
Establishment of human papillomavirus infection requires cell cycle progression. PLoS Pathog (2009) 1.94
The PDZ ligand domain of the human papillomavirus type 16 E6 protein is required for E6's induction of epithelial hyperplasia in vivo. J Virol (2003) 1.91
Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol (2008) 1.91
Reproducibility of skin characteristic measurements and reported sun exposure history. Int J Epidemiol (2002) 1.88
Oral cancer in southern India: the influence of smoking, drinking, paan-chewing and oral hygiene. Int J Cancer (2002) 1.87
Enhanced radiation sensitivity in HPV-positive head and neck cancer. Cancer Res (2013) 1.87
Cigarette smoking and risk of non-Hodgkin lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (interlymph). Cancer Epidemiol Biomarkers Prev (2005) 1.87
Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab (2004) 1.86
Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev (2010) 1.85
Clonorchis sinensis infection and increasing risk of cholangiocarcinoma in the Republic of Korea. Am J Trop Med Hyg (2006) 1.83
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Prevalence and determinants of human papillomavirus infection in men attending vasectomy clinics in Mexico. Int J Cancer (2006) 1.75
Structural and functional consequences of glutamine tract variation in the androgen receptor. Hum Mol Genet (2004) 1.74
Cigarette, cigar, and pipe smoking and the risk of head and neck cancers: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Am J Epidemiol (2013) 1.73
Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc Natl Acad Sci U S A (2005) 1.72
Dietary folate and risk of prostate cancer in Italy. Cancer Epidemiol Biomarkers Prev (2005) 1.72
Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica (2004) 1.72
Human papillomavirus infection among women in South and North Vietnam. Int J Cancer (2003) 1.71
Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer (2003) 1.71
Sexual behaviours and the risk of head and neck cancers: a pooled analysis in the International Head and Neck Cancer Epidemiology (INHANCE) consortium. Int J Epidemiol (2009) 1.70
Infections and cancer: established associations and new hypotheses. Crit Rev Oncol Hematol (2008) 1.70
Hepatitis C virus and risk of lymphoma and other lymphoid neoplasms: a meta-analysis of epidemiologic studies. Cancer Epidemiol Biomarkers Prev (2006) 1.69
A genome-wide association study of upper aerodigestive tract cancers conducted within the INHANCE consortium. PLoS Genet (2011) 1.68
Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study. Neuroepidemiology (2008) 1.68
Coffee and tea intake and risk of oral, pharyngeal and esophageal cancer. Oral Oncol (2003) 1.67
Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS (2008) 1.66
Coffee and tea intake and risk of head and neck cancer: pooled analysis in the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev (2010) 1.63
The role of type of tobacco and type of alcoholic beverage in oral carcinogenesis. Int J Cancer (2004) 1.63
Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. Int J Cancer (2004) 1.62
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. Blood (2003) 1.62
Risk factors for oral and pharyngeal cancer in young adults. Oral Oncol (2004) 1.62
Development of a sensitive and specific assay combining multiplex PCR and DNA microarray primer extension to detect high-risk mucosal human papillomavirus types. J Clin Microbiol (2006) 1.61
Food groups and renal cell carcinoma: a case-control study from Italy. Int J Cancer (2007) 1.60
Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. AIDS (2008) 1.60
Fried potatoes and human cancer. Int J Cancer (2003) 1.58
Nutrient-based dietary patterns and the risk of oral and pharyngeal cancer. Oral Oncol (2010) 1.58
Human papillomavirus, human immunodeficiency virus and immunosuppression. Vaccine (2012) 1.58
Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci U S A (2006) 1.57
Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer (2013) 1.57
Influence of the Mediterranean diet on the risk of cancers of the upper aerodigestive tract. Cancer Epidemiol Biomarkers Prev (2003) 1.55
The minor capsid protein L2 contributes to two steps in the human papillomavirus type 31 life cycle. J Virol (2005) 1.53
Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol (2005) 1.51
Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus-transgenic mouse model. Proc Natl Acad Sci U S A (2005) 1.50
Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer (2014) 1.50
Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle. J Virol (2003) 1.49
Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol (2013) 1.48
Human papillomavirus and cervical cancer. Lancet (2013) 1.48
Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis (2003) 1.47
Multiple human papillomavirus infections: the exception or the rule? J Infect Dis (2011) 1.47
Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer (2003) 1.46
Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev (2007) 1.45
Human papillomavirus infection in women in Shenzhen City, People's Republic of China, a population typical of recent Chinese urbanisation. Int J Cancer (2007) 1.45